| Name | Title | Contact Details |
|---|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Hitachi Chemical Research Ctr. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dannemiller Memorial Educational foundation is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitalz is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Austin, TX. To find more information about Vitalz, please visit www.vitalz.com
GlobalMed Group is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.